Clopixol (zuclopenthixol) / Lundbeck - LARVOL DELTA

Greenness, Blueness, and Whiteness Assessment of Novel Chromatographic Methods for Separation and Simultaneous Analysis of Zuclopenthixol and Its Major Potentially Toxic Impurity: A Comparative Study. (PubMed, Biomed Chromatogr) - "The practicality of the analytical methods was evaluated using the Blue Applicability Grade Index. Additionally, the analytical whiteness was determined via the RGB algorithm."

Clinical • Journal • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry • Schizophrenia

Priapism following antipsychotic-gabapentinoid combination in a case of treatment-resistant schizophrenia: a case report. (PubMed, BMC Psychiatry) - "Priapism requires urgent recognition and management to prevent long-term complications. In psychiatric settings, clinicians should exercise caution when combining gabapentinoids alongside antipsychotics, as this may increase the risk of priapism. This case highlights the need for careful monitoring when prescribing gabapentinoids to patients on long-term antipsychotics, particularly in psychiatric inpatient settings where delayed recognition may increase morbidity."

Journal • CNS Disorders • Critical care • Neuralgia • Pain • Psychiatry • Schizophrenia

Clozapine rechallenge after clozapine-induced myocarditis: A case report to validate a previously published protocol. (PubMed, Ment Health Clin) - "This case differed from the previously published research protocol in some respects, including the concurrent use of zuclopenthixol for antiaggression and no significant eosinophil-related concerns during monitoring. Limitations of the case include unknown postdischarge outcomes and lack of measurement-based care, such as the use of rating scales, to assess treatment response objectively. This case report validates the previously published protocol and contributes to the literature on CIM rechallenge, helping clinicians weigh the risks and benefits of rechallenging clozapine in select patients."

Journal • Cardiovascular • CNS Disorders • Dermatology • Inflammation • Psychiatry • Schizophrenia

POSSIBILITIES OF PSYCHOPHARMACOLOGICAL CORRECTION OF BEHAVIORAL DISORDERS ACCORDING TO THE HYSTEROSHIZOID TYPE OF PATIENTS WITH A CONSTITUTIONAL RANGE OF PERSONALITY DISORDERS (WCN 2025) - "Consequently,in patients with a constitutional range of PH,hysteroschizoid behavioral disorders statistically reliably confirm the psychopharmacorrective efficacy of a combination of quetiapine and clopixol depot.In the case of persistent and pronounced hysteroschizoid behavioral symptoms, statistically effective psychopharmacological correction may be limited to a combination of quetiapine and double administration of clopixol-akufaz."

Clinical • Behavior Disorders • CNS Disorders • Mental Retardation • Mood Disorders • Personality Disorder • Psychiatry • Schizophrenia

POSSIBILITIES OF PSYCHOPHARMACOLOGICAL CORRECTION OF BEHAVIORAL DISORDERS OF THE HYSTEROSCHIZOID TYPE IN PATIENTS WITH A CONSTITUTIONAL RANGE OF BORDERLINE ABNORMAL PERSONALITY (WCN 2025) - "Thus,the greatest effectiveness of psychopharmacorrection of unstable and abortive behavioral hysteroschizoid disorders in patients with a constitutional PAL range is observed when using a low dose of 25 mg of quetiapine in combination with a double parenteral administration of clopixol-akufaz."

Clinical • Behavior Disorders • CNS Disorders • Mental Retardation • Psychiatry • Schizophrenia

Antipsychotic use and risk for hip fracture in individuals with and without schizophrenia: a population-based nested case-control cohort study (ECNP 2025) - "Finally, individual antipsychotic agents were extracted and analyzed to show which has higher odds for hip fracture, while the reference group was Olanzapine...Among the antipsychotic agents odds were significantly higher with the use of Haloperidol and Zuclopenthixol (OR 1.42; 95% CI=1.26-1.62, OR 1.28; 96% CI=1.12-1.48, respectively)... Our findings suggest that both schizophrenia and antipsychotic treatment independently increase the risk of hip fractures, with the highest risk observed among patients treated with antipsychotics regardless of schizophrenia diagnosis. These results highlight the need for clinicians to evaluate fracture risk when prescribing antipsychotics, particularly for off-label indications. Further studies are needed to investigate underlying mechanisms and guide risk-reduction strategies such as bone health monitoring and fall prevention."

Clinical • CNS Disorders • Psychiatry • Schizophrenia • DRD2

A case of creutzfeldt-jakob disease presenting with psychiatric symptoms (ECNP 2025) - "He received quetiapine 300 mg/day orally and risperidone drops 2 mg/2 cc, along with two injections of zuclopenthixol acetate (50 mg/ml). Psychiatric symptoms are common in both sCJD and variant CJD and may include psychosis, depressive symptoms, suicidal ideation, anhedonia, anxiety, delusions, and catatonia. Although psychiatric symptoms have traditionally been considered rare, current literature suggests a higher prevalence [5]."

Clinical • Alzheimer's Disease • Ataxia • CNS Disorders • Cognitive Disorders • Dementia • Depression • Mood Disorders • Movement Disorders • Psychiatry • Sleep Disorder • Suicidal Ideation • CRP • PRNP

Delirious mania with catatonic features as a presenting syndrome of anti-NMDAR encephalitis: a case report (ECNP 2025) - "Despite sequential trials of olanzapine (up to 20 mg/day), quetiapine XR (up to 300 mg/day), zuclopenthixol decanoate (150 mg intramuscular every months), paliperidone (6 mg/day), and adjunctive lithium carbonate (900 mg/day, there was no clinical improvement...Rituximab was started for long-term immunomodulation, maintaining remission over one year...ConclusionA comprehensive neurodiagnostic evaluation enables early diagnosis and treatment of anti-NMDAR encephalitis. Clinicians should consider autoimmune causes in atypical neuropsychiatric cases.[5]"

Case report • Clinical • Ataxia • Bipolar Disorder • CNS Disorders • Epilepsy • Mental Retardation • Mood Disorders • Movement Disorders • Psychiatry

Prescribing patterns of antipsychotic monotherapy and polypharmacy in patients with psychotic disorders (ECNP 2025) - "Among monotherapy patients, olanzapine was most frequently prescribed (33.3%), followed by risperidone and haloperidol (both 18.2%), quetiapine (15.2%), aripiprazole (9.1%), and clozapine (6.1%)...Less frequently prescribed in polytherapy were aripiprazole (10.4%), risperidone (7.3%), levomepromazine and zuclopenthixol (both 6.3%), fluphenazine (4.2%), and amisulpride and sulpiride (both 1.0%)... Despite guideline recommendations that advocate for antipsychotic monotherapy whenever possible [1,3], this study found that polypharmacy remains prevalent in clinical practice. Olanzapine emerged as the most common choice in monotherapy regimens, while haloperidol and promazine were more frequently used in polytherapy. Clozapine, despite its well-established role in treatment-resistant schizophrenia, was more commonly prescribed as part of combination therapy (16.7%) than as monotherapy (6.1%)."

Clinical • Monotherapy • CNS Disorders • Psychiatry • Schizophrenia

Psychiatric manifestations of metachromatic leukodystrophy: a differential for atypical presentations of psychosis? (ECNP 2025) - "During his admission he was trialled on quetiapine, clozapine and zuclopenthixol depot. Diagnosing adult-onset MLD can be notoriously difficult due to the plethora of investigations required and there are often long delays between first presentation and appropriate treatment [5]. Whilst MLD is a rare cause of psychosis, this case illustrates how it may be considered as a differential diagnosis in atypical first presentations of psychosis."

CNS Disorders • Mental Retardation • Psychiatry

Pharmacological treatment among involuntary psychiatric patients: real-world patterns of polypharmacy (ECNP 2025) - "Benzodiazepines were prescribed to 13 participants including diazepamum (54%, n=7), clonazepamum (31%, n=4), and lorazepamum (15%, n=2). Mood stabilizers such as acidum valproic, carbamazepine and oxcarbazepine were used by 58% (n=51) of the study participants...The most observed polypharmacy combinations included: haloperidol + zuclopenthixol depot + clozapine + cyclodol (n=4), haloperidol + zuclopenthixol depot + Acidum Valproic + cyclodol (n=4), and haloperidol + quetiapine + cyclodol (n=3)... The study results highlight a high prevalence of polypharmacy among involuntarily treated patients. In our study BNF coefficient results exceeded recommended daily limits raising concerns about prescribed medication safety, tolerability and therapy adherence. The results reflect the need to establish psychiatric hospitals' recommendations that optimize therapeutic interventions for involuntarily admitted patients ensuring a balance between clinical effectiveness and rational..."

Clinical • Real-world • Real-world evidence • CNS Disorders • Psychiatry • Schizophrenia

Antipsychotics and other risk factors for mortality among people with schizophrenia during an extreme heat event: a population-based case-control study. (PubMed, Sci Rep) - "Dispensation of any antipsychotic was associated with increased EHE mortality [OR 2.43, 95% CI 1.52, 4.01], which was driven by haloperidol, clozapine, and zuclopenthixol. There were also significant non-pharmaceutical risk factors. People with schizophrenia are at-risk during EHEs due to multiple overlapping factors, including antipsychotic medications."

Journal • CNS Disorders • Psychiatry • Schizophrenia

Strategic and tactic use of antipsychotic medications in schizophrenia: a perspective on current prescription practice. (PubMed, Discov Ment Health) - "Meta-analyses indicate clozapine, amisulpride, olanzapine, and risperidone as effective in acute settings, with olanzapine and haloperidol beneficial for SZ-related agitation. Empirical observations suggest higher potency APs, like olanzapine and haloperidol, are more effective in acute psychosis, with zuclopenthixol also advantageous for its sedative properties...Once the acute phase resolved, patients should be gradually switched towards a medication with fewer side effects (i.e. metabolic syndrome, extrapyramidal symptoms, hyperprolactinemia) and a potential efficacy on negative symptoms and personal functioning (i.e. cariprazine, low-dose amisulpride, lurasidone, aripiprazole, brexpiprazole), to be continued in the long term, defined as a strategic AP. This approach aligns with empirical observations and aims to refine schizophrenia care through phase-specific APs use, necessitating further studies to validate its efficacy."

Journal • Review • Anesthesia • CNS Disorders • Metabolic Disorders • Psychiatry • Psychomotor Agitation • Schizophrenia

Use of TLC and Computational Methods to Determine Lipophilicity Parameters of Selected Neuroleptics: Comparison of Experimental and Theoretical Studies. (PubMed, Pharmaceuticals (Basel)) - "Aim: Taking into account the importance of this parameter, we aimed to assess and compare the utility of a hybrid procedure based on calculation methods and an experimental one for rapid and simple estimation of the lipophilicity of selected neuroleptics such as fluphenazine, triflupromazine, trifluoperazine, flupentixol and zuclopenthixol and their potential new derivatives. Our results provide a confident proposal of optimal chromatographic conditions to experimentally determine the lipophilicity of neuroleptic drugs, including new derivatives. Additionally, for the first time, the paper shows the application of selected topological indices in determining lipophilicity factors and other ADMET parameters of neuroleptics and, in the future, the newly synthesized quinoline derivatives of the studied compounds."

Journal

Correlations between receptor occupancy change and mental state in patients using long-acting injectable antipsychotics: MIDILIA pilot study. (PubMed, BJPsych Open) - "Our novel observational study design has been demonstrated to be feasible and practicable. Faster reductions in D2 occupancy may increase the risk of increased positive psychotic symptoms and irritability. Slower reductions may minimise this effect. Further recruitment is required before this can be confirmed."

Journal • CNS Disorders • Psychiatry

DREAMS-Phen: Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach (clinicaltrials.gov) - P2 | N=288 | Not yet recruiting | Sponsor: University Hospital, Strasbourg, France

New P2 trial • CNS Disorders • Psychiatry • Schizophrenia

Antipsychotic medication for behaviors that challenge in individuals with intellectual disabilities: a clinically informed review. (PubMed, Front Psychiatry) - "Observational studies generally supported the short-term effectiveness of risperidone, olanzapine, and zuclopenthixol in reducing aggressive behaviors, although evidence for their impact on self-injurious behaviors (SIBs) was inconsistent...Preliminary open-label evidence suggested that aripiprazole may reduce BC in individuals with Fragile X Syndrome (FXS), while causing fewer metabolic side effects...Overall, the results support cautious and individualized prescribing, with close monitoring of adverse effects and attention to deprescribing when appropriate. Further longitudinal and naturalistic studies are warranted, along with the development of structured tools to assist clinicians in optimizing pharmacological care for this vulnerable population."

Journal • Review • Anesthesia • CNS Disorders • Developmental Disorders • Fragile X Syndrome • Genetic Disorders • Mental Retardation

Sexual dysfunctions related to use of antipsychotics: A protocol for a systematic review and meta-analysis. (PubMed, PLoS One) - "The antipsychotic medications of interest are amisulpride, aripiprazole, asenapine, brexpiprazole, cariprazine, chlorpromazine, clopenthixol, clozapine, droperidol, flupenthixol, fluphenazine, haloperidol, iloperidone, levomepromazine, loxapine, lurasidone, molindone, olanzapine, paliperidone, penfluridol, perphenazine, perazine, pimozide, prochlorperazine, quetiapine, risperidone, sertindole, sulpiride, thiothixene, thioridazine, trifluoperazine, ziprasidone, zuclopenthixol and zotepine. The Cochrane Risk of Bias tool and RoB 2.0 will be used to assess the risk of bias in studies. We will evaluate the quality of the evidence contributing to network estimates for the primary outcomes using the GRADE framework, and key factors that may affect the observed effects will be analysed for consistency across studies."

Journal • Retrospective data • CNS Disorders • Sexual Disorders • PRL

RAKGEORREC: Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR. (clinicaltrials.gov) - P4 | N=40 | Recruiting | Sponsor: Dr. Stavroula Rakitzi

New P4 trial • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry • Schizophrenia

Zuclopenthixol decanoate induced dysphagia. (PubMed, BMJ Case Rep) - "This case report describes a patient with known bipolar affective disorder who had been recently stabilised on zuclopenthixol decanoate and presented with sudden onset severe oropharyngeal dysphagia. Symptoms spontaneously resolved with the discontinuation of the medication, and this report explores the suggested underlying mechanisms from literature."

Journal • Bipolar Disorder • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Psychiatry

Long-term effectiveness, adherence and safety of twice-yearly paliperidone-palmitate long acting-injectable in patients with schizophrenia in Europe: 2-year mirror-image data from the paliperdone-2 per year study (P2Y). (PubMed, Front Psychiatry) - "The majority of patients had switched to PP6M from either PP3M (76%) or PP1M (19%) while the 3% switched from aripiprazole 1-monthly and the 2% from risperidone-LAI and zuclopenthixol-LAI. Nonetheless, we were unable to determine the precise changes in symptoms. Therefore, future studies are needed to truly establish the role of PP6M."

Journal • CNS Disorders • Psychiatry • Schizophrenia

The Effect of Age on Antipsychotic Serum Concentration in Males and Females: A Study Based on Therapeutic Drug Monitoring Data From 19,926 Patients. (PubMed, Ther Drug Monit) - "The age-dependent increase in dose-adjusted serum concentrations among males and females varied across different antipsychotics and was highest for risperidone. These findings emphasize the importance of proper monitoring of antipsychotic use in older adults."

Journal • CNS Disorders

Addition of long-acting injectable antipsychotics during manic episodes in bipolar disorder: A retrospective analysis of rehospitalizations. (PubMed, J Affect Disord) - "Our findings suggest that the addition of LAIs for bipolar mania during acute inpatient treatment is associated with reduced rehospitalizations, particularly among patients with recurrent hospitalizations, making it a valuable option. However, the lack of outpatient prescription data limits our ability to further substantiate this concept, warranting future research."

Journal • Retrospective data • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry

Lurasidone versus typical antipsychotics for schizophrenia. (PubMed, Cochrane Database Syst Rev) - "We are very uncertain about whether lurasidone offers benefits to the mental state, total serious adverse events, or severe adverse events when compared to typical antipsychotics for people with schizophrenia. The evidence included in this review is of very low certainty, derived from two small trials. Study limitations (risk of bias) and imprecise results impacted our confidence in the evidence. Furthermore, data on mortality (due to suicide or natural causes) or quality of life are unavailable. Further large-scale randomized studies are needed to provide clearer insights into the benefits and harms of lurasidone compared to typical antipsychotics for treating schizophrenia."

Clinical • Journal • Review • CNS Disorders • Psychiatry • Schizophrenia

Zuclopenthixol reduces activity-dependent glioblastoma proliferation (SNO 2024) - "We show that zuclopenthixol treatment significantly reduced the proliferation index. Our experimental model allowed the optimization of organotypic human cortical slice cultures for immunofluorescence studies and live-cell imaging."

Brain Cancer • CNS Disorders • CNS Tumor • Glioblastoma • Oncology • Solid Tumor